MC 1101

Drug Profile

MC 1101

Alternative Names: MC-1101; SB 04

Latest Information Update: 09 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Texas A&M University
  • Developer MacuCLEAR; Mystic Pharmaceuticals
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration

Most Recent Events

  • 09 Jun 2016 Phase-II/III development is ongoing in USA
  • 19 Apr 2016 Mystic Pharmaceuticals has patent protection for its drug delivery platform technology, VersiDoser® in USA
  • 03 Jun 2015 SynCore Biotechnology enters into an agreement with AJU Pharm for co-development and commercialization of MC 1101 in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top